These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

876 related articles for article (PubMed ID: 33217030)

  • 21. Combinatorial approach of vitamin C derivative and anti-HIV drug-darunavir against SARS-CoV-2.
    Sahoo A; Swain SS; Paital B; Panda M
    Front Biosci (Landmark Ed); 2022 Jan; 27(1):10. PubMed ID: 35090315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.
    Barnabas RV; Brown ER; Bershteyn A; Stankiewicz Karita HC; Johnston C; Thorpe LE; Kottkamp A; Neuzil KM; Laufer MK; Deming M; Paasche-Orlow MK; Kissinger PJ; Luk A; Paolino K; Landovitz RJ; Hoffman R; Schaafsma TT; Krows ML; Thomas KK; Morrison S; Haugen HS; Kidoguchi L; Wener M; Greninger AL; Huang ML; Jerome KR; Wald A; Celum C; Chu HY; Baeten JM;
    Ann Intern Med; 2021 Mar; 174(3):344-352. PubMed ID: 33284679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment.
    Swain SS; Singh SR; Sahoo A; Hussain T; Pati S
    J Biomol Struct Dyn; 2022 Sep; 40(14):6463-6476. PubMed ID: 33583350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study.
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2022 Mar; 40(5):2053-2066. PubMed ID: 33094701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
    Inciarte A; Leal L; González E; León A; Lucero C; Mallolas J; Torres B; Laguno M; Rojas J; Martínez-Rebollar M; González-Cordón A; Cruceta A; Arnaiz JA; Gatell JM; García F;
    J Antimicrob Chemother; 2017 Oct; 72(10):2857-2861. PubMed ID: 29091217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
    La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
    Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The characteristics of HIV-positive patients with mild/asymptomatic and moderate/severe course of COVID-19 disease-A report from Central and Eastern Europe.
    Kowalska JD; Kase K; Vassilenko A; Harxhi A; Lakatos B; Lukić GD; Verhaz A; Yancheva N; Dumitrescu F; Jilich D; Machala L; Skrzat-Klapaczyńska A; Matulionyte R
    Int J Infect Dis; 2021 Mar; 104():293-296. PubMed ID: 33326871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies.
    Kala S; Dunk C; Acosta S; Serghides L
    Hum Reprod; 2020 Aug; 35(8):1781-1796. PubMed ID: 32712670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1,2,4 triazolo[1,5-a] pyrimidin-7-ones as novel SARS-CoV-2 Main protease inhibitors: In silico screening and molecular dynamics simulation of potential COVID-19 drug candidates.
    Kavitha K; Sivakumar S; Ramesh B
    Biophys Chem; 2020 Dec; 267():106478. PubMed ID: 33022567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 research: an opinion piece.
    Waters L; Rockstroh JK
    HIV Med; 2020 Sep; 21(8):536-540. PubMed ID: 32544304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
    Martorana A; Gentile C; Lauria A
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Characteristics of antiretroviral drugs].
    Ribera E; Tuset M; Martín M; del Cacho E
    Enferm Infecc Microbiol Clin; 2011 May; 29(5):362-91. PubMed ID: 21531048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
    Foo CS; Abdelnabi R; Kaptein SJF; Zhang X; Ter Horst S; Mols R; Delang L; Rocha-Pereira J; Coelmont L; Leyssen P; Dallmeier K; Vergote V; Heylen E; Vangeel L; Chatterjee AK; Annaert PP; Augustijns PF; De Jonghe S; Jochmans D; Gouwy M; Cambier S; Vandooren J; Proost P; van Laer C; Weynand B; Neyts J
    Antiviral Res; 2022 Jun; 202():105311. PubMed ID: 35390430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2021 Aug; 39(12):4362-4374. PubMed ID: 32568613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
    Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
    Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.
    Ford N; Shubber Z; Calmy A; Irvine C; Rapparini C; Ajose O; Beanland RL; Vitoria M; Doherty M; Mayer KH
    Clin Infect Dis; 2015 Jun; 60 Suppl 3():S170-6. PubMed ID: 25972499
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.